Understanding the Link Between GLP-1s, Osteoporosis, and Gout
Published: 10 Mar 2026
Author: Precedence Research
GLP-1 drugs, including Ozempic and Wegovy, may be linked to a slightly higher risk of osteoporosis and gout, according to a study presented at the annual meeting of the American Academy of Orthopaedic Surgeons Dr. John Horneff, the lead author of the study at the University of Pennsylvania, said he began investigating the issue after some patients appeared to develop severe tendon ruptures after relatively small injuries.
In a new study, researchers analysed five years of medical records of more than 146,000 adults diagnosed with obesity and type 2 diabetes.
The study compared patients taking GLP-1 drugs, such as semaglutide and liraglutide, to those who did not take these drugs. However, detailed information on the specific GLP-1 drugs that each patient takes has not been documented.
According to Precedence Research, the Bone Densitometer Devices Market accounted for USD 370.00 million in 2025 and is predicted to increase from USD 384.99 million in 2026 to approximately USD 550.33 million by 2035, expanding at a CAGR of 4.05% from 2026 to 2035 as demand for precise diagnosis grows faster.
Consumers of GLP-1 drugs have a 30% increased risk of osteoporosis (4% versus just over 3%) and twice the incidence of osteomalacia compared to non-users. The incidence of gout among GLP-1 users is also higher, at 7.4% compared to 6.6% in non-users, reflecting a 12% increase in risk. However, due to the observational nature of the study, a direct causal link to osteoporosis or gout cannot be established. Previous studies also indicate a higher risk of fractures related to osteoporosis in older adults with type 2 diabetes who are taking GLP-1 drugs. Limitations of the study include a lack of data on diet, exercise, and vitamin D intake.
The FDA's Semaglutide label points to the potential increase in the risk of bone fractures in older adults and women. Susan Spratt raised concerns about whether this risk is caused by rapid weight loss or other factors that separate joint health and bone density. Dr. Christopher McGowan pointed out that patients maintain control over health management despite the increased risks of GLP-1 drugs.
Horneff suggests that GLP-1 drugs may affect the risk of bone and diarrhea, as the suppression of appetite and rapid weight loss reduce important bone nutrients and temporarily increase the concentration of urine, although more research is needed to confirm this. The study shows that lifestyle factors are crucial. The implication is not fear, it is refinement.
A recent report by Precedence Research highlights that the Bone Densitometer Devices Market is benefiting from healthcare awareness and technological advancements.